GenVec (NASDAQ: GNVC) is one of 187 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare GenVec to related companies based on the strength of its institutional ownership, earnings, dividends, risk, valuation, profitability and analyst recommendations.
Insider & Institutional Ownership
6.2% of GenVec shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 8.1% of GenVec shares are owned by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares GenVec and its rivals top-line revenue, earnings per share and valuation.
GenVec’s rivals have higher revenue, but lower earnings than GenVec. GenVec is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a summary of recent recommendations for GenVec and its rivals, as reported by MarketBeat.
||Strong Buy Ratings
GenVec currently has a consensus target price of $7.00, suggesting a potential downside of 2.64%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.01%. Given GenVec’s rivals stronger consensus rating and higher possible upside, analysts clearly believe GenVec has less favorable growth aspects than its rivals.
This table compares GenVec and its rivals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
GenVec rivals beat GenVec on 9 of the 11 factors compared.
GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company’s lead product candidate is CGF166. The Company’s vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
Receive News & Ratings for GenVec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenVec and related companies with MarketBeat.com's FREE daily email newsletter.